Patients with any grade 3 or higher toxicity by tested compound category for phase 2 trials Ν **Proportion** 95%-CI Effect size Antiangiogenesis 1 86.7 (69.4; 94.9) Chemotherapy 8 (13.3; 45.0)26.1 **Immunomodulator** 10 (19.1; 46.0) 31.0 Other 3 54.1 (46.2; 61.9) Receptor or signal transduction 32 42.6 (32.9; 52.8)Vaccine 2 2.8 (0.7; 10.5)Overall 56 38.1 (31.6; 45.0)



0 100 Effect size (95%–CI)